Bioadaptives annual stock-based compensation
2013
2014
2015
2018
2019
2020
2021
2022
2025
Bioadaptives Stock-Based Compensation Growth & History (BDPT)
Bioadaptives's stock-based compensation was $28,670 for fiscal 2025.
View full Bioadaptives company overviewBioadaptives annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28,670 | — | — |
| 2022 | 2022-12-31 | $0 | −$163,900 | — |
| 2021 | 2021-12-31 | $163,900 | $116,785 | +247.87% |
| 2020 | 2020-12-31 | $47,115 | −$45,677 | −49.23% |
| 2019 | 2019-12-31 | $92,792 | −$179,893 | −65.97% |
| 2018 | 2018-12-31 | $272,685 | — | — |
| 2015 | 2015-12-31 | $49,692 | −$1.6M | −96.97% |
| 2014 | 2014-12-31 | $1.6M | $1.6M | +164150.00% |
| 2013 | 2013-12-31 | $1,000 | — | — |
Bioadaptives quarterly stock-based compensation
Q2.13
Q3.13
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q2.22
Q3.22
Q2.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $28,670 | — | — |
| Q3 2022 | 2022-09-30 | $0 | $0 | — |
| Q2 2022 | 2022-06-30 | $0 | $0 | — |
| Q4 2021 | 2021-12-31 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $0 | $0 | — |
| Q2 2021 | 2021-06-30 | $0 | −$46,264 | — |
| Q1 2021 | 2021-03-31 | $163,900 | $116,785 | +247.87% |
| Q3 2020 | 2020-09-30 | $0 | −$23,198 | — |
| Q2 2020 | 2020-06-30 | $46,264 | $25,264 | +120.30% |
| Q1 2020 | 2020-03-31 | $47,115 | $26,115 | +124.36% |
| Q4 2019 | 2019-12-31 | $27,594 | — | — |
| Q3 2019 | 2019-09-30 | $23,198 | −$62,072 | −72.79% |
| Q2 2019 | 2019-06-30 | $21,000 | — | — |
| Q1 2019 | 2019-03-31 | $21,000 | — | — |
| Q3 2018 | 2018-09-30 | $85,270 | — | — |
| Q3 2016 | 2016-09-30 | $13,869 | $2 | +0.01% |
| Q2 2016 | 2016-06-30 | $13,719 | −$1 | −0.01% |
| Q1 2016 | 2016-03-31 | $13,719 | $5,729 | +71.70% |
| Q4 2015 | 2015-12-31 | $14,115 | — | — |
| Q3 2015 | 2015-09-30 | $13,867 | $13,867 | — |
| Q2 2015 | 2015-06-30 | $13,720 | −$40,280 | −74.59% |
| Q1 2015 | 2015-03-31 | $7,990 | — | — |
| Q3 2014 | 2014-09-30 | $0 | $0 | — |
| Q2 2014 | 2014-06-30 | $54,000 | $53,000 | +5300.00% |
| Q3 2013 | 2013-09-30 | $0 | — | — |
| Q2 2013 | 2013-06-30 | $1,000 | — | — |
Bioadaptives stock-based compensation trends
Over the last five fiscal years, Bioadaptives's stock-based compensation decreased from $47,115 to $28,670, a change of −$18,445. The latest reported quarter, Q2 2025, shows $28,670.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioadaptives source filings ↗